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MitosisMitotic progression is regulated by co-ordinated action of several proteins and is crucial for the maintenance of
genomic stability. CHFR (Check point protein with FHA and RING domains) is an E3 ubiquitin ligase and a check-
point protein that regulates entry into mitosis. But the molecular players involved in CHFR mediated mitotic
checkpoint are not completely understood. In this study, we identiﬁed TOPK/PBK, a serine/threonine kinase
and PTEN, a lipid phosphatase to play an important role in CHFRmediatedmitotic transitions. We demonstrated
that CHFR ubiquitinates and regulates TOPK levels, which is essential for its checkpoint function. Moreover, TOPK
phosphorylates and inactivates PTEN, which in turn activates Akt that leads to proper G2/M progression. Collec-
tively, our results reveal TOPK and PTEN as new players in CHFR mediated mitotic checkpoint.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license. 1. Introduction
CHFR is a well deﬁned mitotic checkpoint protein that delays entry
into mitosis in response to stress [1]. The role of CHFR in mitotic check-
point is attributed to its function as an E3 ligase, which ubiquitinates
and degrades its target proteins. Currently CHFR is known to regulate
the stability of very limited substrates such as Aurora A, Plk1, Kif22
and PARP1, which are critical for proper mitotic transitions. In addi-
tion to its proteosomal substrates, CHFR was also shown to regulate
checkpoint in a proteosomal independent manner [2]. For instance
ubiquitylation-dependent activation of p38 kinase but not proteasome
dependent degradation by CHFR contributes to its checkpoint [3]. Also
CHFR controls mitotic transitions by regulating the nuclear localization
of cyclin B [4].
So far threemodes of regulation have been reported to control CHFR
mitotic function. Firstly, PML bodieswere shown to control the distribu-
tion, dynamics and mitotic checkpoint function of CHFR [5]. Secondly
Akt phosphorylates CHFR and may promote its autoubiquitination
activity and thus inhibits its checkpoint function [6]. Finally, polyADP-
ribosylated substrates catalyzed by PARP1 bind to CHFR via its PBZ-
motif and thus may be required for its function in ante-phase check-
point [7].91 40 24749448.
. Open access under CC BY license. To elucidate potential substrates and/or regulators of CHFR during
its mitotic checkpoint function, we recently performed a tandem afﬁn-
ity puriﬁcation using a 293 T cell line stably expressing the triple tagged
(S-protein, FLAG, and Streptavidine-binding peptide) version of CHFR
(SFB-CHFR) and identiﬁed several CHFR associated proteins by mass
spectrometric analysis [8]. We repeatedly found TOPK as one of the po-
tential CHFR associated proteins. TOPK (lymphokine-activated killer T-
cell-originated protein kinase) also known as PBK (PDZ-binding kinase)
is a MAPKK-like serine/threonine kinase that was originally identiﬁed
as a gene that is differentially expressed in IL-2 lymphokine-activated
killer T (T-LAK) cells [9]. TOPK is shown to be upregulated duringmito-
sis and its phosphorylation at Threonine 9 residue by cdk1/cyclin B is
crucial for its mitotic function [10]. Several studies have indicated that
TOPK might be a potential oncogene [11]. Overexpression of TOPK has
been reported in various human cancers including lung cancer, breast
cancer and lymphomas [12–14]. However, the downstream players in
TOPK mediated mitotic progression are poorly understood.
2. Results
2.1. TOPK is a novel CHFR associated protein
We conﬁrmed the association of TOPK with CHFR by co-immuno
precipitation experiments. Endogenous CHFR was found to be associat-
ed with exogenously expressed Flag-tagged TOPK in 293 T cells and on
the other hand endogenous TOPKwas found in the immunoprecipitated
CHFR complex (Fig. 1a). Further, we showed that TOPK interacts with
bacterially expressed recombinant GST–CHFR but not with GST alone
thus conﬁrming the association of TOPK and CHFR (Fig. 1b). In order
to map the TOPK binding region on CHFR, we generated full length
CHFR along with CHFR deletion mutants that lack various domains
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Fig. 1. TOPK is a novel CHFR associated protein. (a) 293 T cellswere transfectedwith Flag-tagged TOPK (upper panel) or Flag-taggedCHFR (lower panel). The interaction of CHFR and TOPK
was detected by immunoblotting with anti-CHFR and anti-TOPK antibodies after immunoprecipitation with anti-IgG and anti-Flag antibodies. (b) The in vitro interaction of endogenous
TOPK with CHFR was detected by immunoblotting with anti-TOPK antibody after performing GST pull down assay with either GST or GST–CHFR using 293 T cell lysate. (c) Schematic
representation of domain architecture of full length CHFR, along with its various deletion mutants. (d) 293 T cells were co-transfected with the indicated Myc-tagged CHFR
constructs along with Flag-tagged TOPK and the interaction was determined by immunoprecipitation and immunoblotting with the indicated antibodies. (e) Schematic representation
of N-terminal Flag-tagged full-length TOPK, along with its various deletion mutants. (f) 293 T cells were co-transfected with the indicated Flag-tagged TOPK constructs along with
those encoding Myc tagged CHFR and the interaction between TOPK and CHFR was determined by immunoprecipitation and immunoblotting with the indicated antibodies.
2512 S.R. Shinde et al. / Cellular Signalling 25 (2013) 2511–2517(Fig. 1c). Immunoprecipitation data revealed that the TOPK interacted
with full length CHFR, ΔFHA, and ΔRING CHFR mutants but not with
the Δcysteine rich domain mutant of CHFR (Fig. 1d). Similarly, in
order to map the region of interaction of CHFR on TOPK, we generated
expression constructs for FLAG–TOPK and a series of deletion mutants
that lack various regions of TOPK (Fig. 1e). CHFR interactedwith D5mu-
tant in addition to full length TOPK but not with other mutants
suggesting that TOPK region spanning aminoacids 275–322 (C-terminal
to kinase domain) is required for CHFR interaction. Together these re-
sults suggest that CHFR via its C-terminal cysteine rich domain interacts
with TOPK at its C-terminal region (Fig. 1f).2.2. TOPK is a substrate of CHFR
As TOPK was identiﬁed as new associated protein of CHFR, we ini-
tially tested if TOPK regulates CHFR function via its kinase activity, but
we failed to observe any phosphorylation of CHFR by TOPK in a kinase
assay. In addition autoubiquitination assays with CHFR either in the
presence or absence of TOPK revealed no differences in the E3 ligase ac-
tivity of CHFR (S.R.S. & S.M., unpublished data), thus may be ruling out
the possibility of TOPK as a CHFR regulator. Earlier, CHFR was shown
to recruit its substrates such as Aurora A and Kif22 for ubiquitination
and degradation via its C-terminal cysteine rich domain [8,15]. As
2513S.R. Shinde et al. / Cellular Signalling 25 (2013) 2511–2517TOPK also interacts with CHFR cysteine rich domain we next tested if
TOPK is an additional substrate for CHFR E3 ligase activity in cells. Our
in vivo ubiquitination assays revealed that the polyubiquitination of
TOPK occurs only in the presence of full length CHFR but not with the
ΔRING or Δcysteine-rich domain deletion mutants (Fig. 2a). On the
other hand, full length TOPK but not CHFR binding defective mutant
(TOPK D4) was polyubiquitinated by CHFR (Fig. 2b) thus indicating
that TOPK might be a substrate of CHFR, which requires intact CHFR
E3 ligase activity as well as its interaction domain. Polyubiquitination
of TOPK by CHFR is required for its degradation as co-expression of
full length CHFR in HeLa cells, which lack endogenous CHFR, re-
duced protein half-life of TOPK compared to TOPK alone. No change in
TOPK half-life was observed with the CHFR ΔRING deletion mutant
(Fig. 2c). Further CHFR mediated TOPK degradation was dependenta
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Fig. 2. CHFRubiquitinates and degrades TOPK. (a)Myc tagged full length CHFR,ΔRING orΔCyste
andHA tagged ubiquitin. After the 24 hour post transfection, cellswere treatedwithMG132 (10
using streptavidin beads followed by anti-HA immunoblotting. (b) HeLa cells were transient
ubiquitinationwas evaluated by immunoprecipitation using streptavidin beads followed by ant
with cyclohexamide and the lysates were collected at the indicated time points. The levels of T
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The levels of TOPK, CHFR and actin were determined by immunobloting.on proteosome activity as pretreatment of cells with a proteosome
inhibitor MG132 rescued protein half life of TOPK (Fig. 2d). Together
these results suggest that TOPK is an in vivo substrate of CHFR E3 ligase
activity.
2.3. TOPK participates in CHFR mediated mitotic stress check point
In order to check whether TOPK participates in CHFR induced
mitotic check point, we knocked down TOPK in HeLa cells by using
shRNAs speciﬁcally targeting TOPK (Fig. 3a). Cells were treated
with Nocodazole and phospho Histone H3 staining was done after
20 h of Nocodazole release to check the number of cells entering
mitosis. Similar to CHFR mediated mitotic stress checkpoint, knock
down of TOPK in HeLa cells signiﬁcantly reduced the number ofR FL 
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Fig. 3. CHFR delays entry into mitosis in TOPK dependent manner. (a) HeLa cells were transfected with either non-targeting control shRNA or two individual TOPK shRNA containing
vectors. Cell lysates were collected 48 h later and the expression of TOPK was determined by immunoblotting with TOPK antibody. (b) Cells expressing either control or TOPK shRNAs
were treated with Nocodazole for 12 h and later released into a fresh medium. Mitotic index is calculated by scoring phospho-Histone H3 positive cells by immunoﬂuorescence staining
after 20 h ofNocodazole release. (c) HeLa cellswere transfected as indicated and the expression of theCHFR and TOPKwas shownby immunoblotting. (d)HeLa cellswere transfectedwith
CHFR and TOPK as indicated and the mitotic index was calculated as in b.
2514 S.R. Shinde et al. / Cellular Signalling 25 (2013) 2511–2517mitotic cells compared to control cells (Fig. 3b). To further test if
CHFR mediated mitotic stress checkpoint is dependent on TOPK we
over expressed CHFR alone or in combination with full length
TOPK and TOPK D4 mutant in HeLa cells (Fig. 3c) and checked for
the phospho Histone H3 positive cells. As expected, overexpression
of CHFR delayed cell entry into mitosis whereas TOPK enhanced
their entry into mitosis. Interestingly, co-expression of non-degrad-
able TOPK (D4 mutant) along with CHFR signiﬁcantly rescued CHFR
mediated delay into mitosis (Fig. 3d). Together, these results show
that TOPK plays an important role in CHFR mediated mitotic check
point.
2.4. PTEN is phosphorylated by TOPK and is required for mitotic entry
To further understand themechanism of TOPK participation in CHFR
mediated mitotic check point we sought to identify the downstreamFig. 4. TOPK phosphorylates PTEN and is important for mitotic entry. (a) 293 T cell lysate expre
streptavidine sepharose beads and the interaction of PTEN was detected by immunoblotting with
or GST–PTEN using a recombinant TOPK holoenzyme in the presence of [γ-p32] ATP. Samples we
(c) An in vitro kinase assay was performed on puriﬁed wild type PTEN and various PTEN mutant
shown by autoradiography. (d) PTEN phosphorylation was determined by immunoblotting with
containing vectors. (e) Levels of phospho-Akt were determined by immunoblotting with phosph
were released into subsequent cell cycle stages. Cell lysates collected at various times were ana
(g) HeLa cells were transfected as indicated and the expression of the CHFR and PTEN was show
the role of TOPK and PTEN in CHFR mediated mitotic checkpoint.substrates of TOPK in cells. A recent study has suggested that TOPK pro-
motes AKT activation [13] by reducing cellular PTEN levels and other
studies have supported the role of AKT activation in proper G2–M pro-
gression [16,17]. Thus we hypothesized that TOPK may participate in
CHFR mediated mitotic checkpoint by regulating PTEN–Akt pathway.
In an attempt to check whether PTEN is a downstream player in
TOPK pathway, ﬁrst we checked the interaction between TOPK and
PTEN. Our immunoprecipitation results indicate that endogenous
PTEN interacts with TOPK (Fig. 4a). We next tested whether TOPK can
phosphorylate PTEN by using an in vitro kinase assay. Autoradiography
analysis revealed that GST–PTEN but not GST alone was readily phos-
phorylated by recombinant TOPK (Fig. 4b). PTEN was reported to be
heavily phosphorylated in its tail region (aminoacids 360–390) [18].
In order to map the site of phosphorylation we mutated the serine
and threonine residues in this region to alanine. By using various
PTENmutants in a kinase assaywe concluded that TOPKphosphorylatesssing triple tagged TOPK was used for immunoprecipitation by either anti-IgG sepharose or
anti-PTEN antibody. (b) An in vitro kinase assay was performed on bacterially puriﬁed GST
re resolved on 10% SDS-PAGE and PTEN phosphorylation was detected by autoradiography.
s using an active TOPK enzyme in the presence of [γ-p32] ATP and the phosphorylation was
phospho-PTEN antibody using HeLa cells transfected with control shRNA or TOPK shRNA
o-Akt (serine 473) antibody. (f) HeLa cells synchronized in mitosis by Nocodazole treatment
lyzed for the levels of indicated proteins by immunoblotting with their speciﬁc antibodies.
n by immunoblotting. Mitotic index is calculated as in Fig. 3b. (h) Proposed model to show
2515S.R. Shinde et al. / Cellular Signalling 25 (2013) 2511–2517PTEN at S380 residue in vitro (Fig. 4c). By using a phospho speciﬁc anti-
body we further conﬁrmed PTEN phosphorylation at S380 residue in
cells, which is reduced upon TOPK knock down by shRNA (Fig. 4d). In
addition, reduced PTEN phosphorylation levels upon TOPK knockdown
correlated with decreased Akt activation (Fig. 4e) suggesting that TOPK
mediated phosphorylation may lead to PTEN inactivation. This result isa
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2516 S.R. Shinde et al. / Cellular Signalling 25 (2013) 2511–2517and pAkt in different phases of cell cycle. TOPK is highly expressed in
mitosis that correlated with high phospho-PTEN (S380) levels and
phospho-Akt levels compared to other phases of cell cycle (Fig. 4f).
Importantly, phosphorylation of PTEN is required for proper entry into
mitosis as expression of non-phosphorylatable PTEN S380A mutant
signiﬁcantly reduced themitotic cell population (Fig. 4g), which is sim-
ilar to the observed phenotype upon CHFR expression. Taken together
these results suggest that TOPK inactivates PTEN by phosphorylating
S380 residue speciﬁcally during mitosis, which leads to activation of
Akt that is required for proper mitotic progression (Fig. 4h).3. Discussion
In summary, we identiﬁed TOPK and PTEN as two novel players in
CHFR mediated mitotic checkpoint. We demonstrated that CHFR
ubiquitinates and regulates TOPK levels, which is essential for its check-
point function. Moreover, TOPK phosphorylates and inactivates PTEN,
which in turn activates Akt that leads to proper G2 to M progression.
Earlier studies have shown that TOPK is upregulated during mitosis
and is crucial for proper cell cycle progression during this phase [10],
but the molecular mechanism of Akt activation during mitosis is un-
known. Here we have shown that PTEN is an important downstream
substrate for TOPK function for proper mitotic progression. Previous
studies have also shown that PTEN modulates cell cycle progression
by regulating phosphatidylinositol 3,4,5-trisphosphate and Akt signal-
ing pathway [19] but the precise mechanism of PTEN activation/inacti-
vation during particular phase of the cell cycle is not known. Further,
Akt is transiently activated during G1/S and also in G2/M transition
phase [16,20]. Here in our study, we provided evidence to support
PTEN inactivation via its Serine 380 phosphorylation by TOPK speciﬁcal-
ly duringmitosis,which is followed byAkt activation. Thus precise PTEN
inactivation duringmitosis is required for proper cell cycle transition as
cells expressing non-phosphorylatable and constitutively active PTEN
S380A mutant were defective in G2 to M progression.
On the other hand, during G2–M transition CHFR levels were
downregulated by its autoubiquitination activity but the question
remains how CHFR autoubiquitination activity is stimulated during
this particular phase of the cell cycle. Previously it was shown that Akt
phosphorylates CHFR and is known to regulate its mitotic checkpoint
function [6]. It is possible that downstream of PTEN inactivation, Akt
phosphorylates CHFR and stimulates its autoubiquitination activity spe-
ciﬁcally during G2–M transition. Thus based on these data we speculate
that CHFR, TOPK, PTEN and AKT may exist in a feedback loop mecha-
nism to precisely control the mitotic transitions.
Several studies have supported the role of CHFR as a potential tumor
suppressor [21,22]. CHFR has been found to be either lost or down reg-
ulated or its promoter being hypermethylated in several human cancers
including breast, prostate, lung and esophageal cancers. In addition, the
role of CHFR as a tumor suppressor has been substantiated by CHFR
knock-out mice [15], which are cancer prone and develop spontaneous
tumors. In our studies as we found TOPK, an oncogene [11–14] and
PTEN, a well known tumor suppressor [23,24] to play an intricate role
in CHFR functions we speculate that these two proteins may partially
contribute to CHFR tumor suppressor function as well.4. Materials and methods
4.1. Plasmids
Full length PTEN, TOPK, CHFR and domain deletionmutants of CHFR
and TOPK were cloned into Myc and S-protein/FLAG/SBP (streptavidin
binding protein)— triple tagged destination vector using Gateway clon-
ing system (Invitrogen). The pointmutants for PTENwere generated by
PCR-based site-directed mutagenesis and veriﬁed by sequencing.4.2. Antibodies
Anti-PTEN, anti-TOPK, anti-Akt, anti-phospho Akt (Ser 473), anti-
phospho PTEN (Ser380) (all from Cell Signalling Technology), anti-Myc
clone 9E10, anti-GST (Santa Cruz Biotechnologies), anti-Flag, anti-actin,
anti-tubulin, anti-HA (Sigma) and anti-phospho Histone H3 (Ser 10)
antibodies were used in this study.
4.3. Cell transfections, immunoprecipitation and immunoblotting
Cells were transfected with various plasmids using PEI transfection
reagent. For immunoprecipitation assays, the cells were lysed with
NETN buffer (20 mM Tris–HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5%
Nonidet P-40) containing 50 mM β-glycerophosphate, 10 mM NaF,
1 μg/ml of each pepstatin A and aprotinin on ice for 30 min.. The whole
cell lysates obtained by centrifugation were incubated with 2 μg of
speciﬁed antibody bound to either protein A or protein G sepharose
beads (Amersham Biosciences) for 1 h at 4 °C. The immunocomplexes
were then washed with NETN buffer four times and applied to SDS-
PAGE. Immunoblotting was performed following standard protocols.
4.4. Retrovirus production and infection
Retroviral vector containing either control shRNA or TOPK shRNA
(purchased from Open biosystems) along with a PcL-Ampho helper
plasmid was co-transfected in to BOSC23 packing cells. Virus-containing
supernatant was collected 48 and 72 h after transfection and was used
to infect HeLa cells in the presence of polybrene.
4.5. In vitro kinase assay
Bacterially puriﬁed GST–PTEN WT, PTEN T382A, PTEN T383A, PTEN
2 T/A (T382A, T383A), PTEN S380A bound to glutathione–Sepharose
beads (Amersham) were incubated with kinase assay buffer (25 mM
HEPES, 25 mM β-glycerophosphate, 25 mMMgCl2, 2 mMdithiotreitol,
and 0.1 mMNaVO3) in the presence ofγ-p32 labeled ATPwith recombi-
nant TOPK holoenzyme for 60 min at 30 º C. The beads were washed
and proteins were resolved on 10% SDS-PAGE gel followed by autoradi-
ography analysis.
4.6. In vivo ubiquitination assay
HeLa cells were transfected with various combinations of plasmids
as indicated in Fig. 2a. After the 24 hour post-transfection, the cells
were treated with MG132 (10 μM for 6 h) and the whole cell extracts
prepared by NETN lysis were subjected to immunoprecipitation of
the substrate protein. The analysis of ubiquitination was performed by
immunoblotting with anti-ubiquitin antibodies.
4.7. Cell synchronization and mitotic index determination
HeLa cells were treatedwith the Nocodazole (500 ng/ml) for 12 h, a
mitotic shake-off was performed and the cells were reseeded in com-
plete medium for release from the arrest. The analysis of cell cycle was
performed different times post Nocodazole release by ﬂow cytometry
using propidium iodide staining and expression of proteins were de-
tected by immunoblotting. For mitotic index determination cells col-
lected at 20 hour post release were subjected to immunoﬂuorescence
using phospho-Histone H3 antibody using standard protocols. The
phospho-H3 positive cells were counted and percentage of mitotic
cells was plotted.
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